KURA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 106217 min ago

@ $19.65

Wydano: 14 vas. 2024 @ 22:45

Zwrot: 0.00%

Poprzedni sygnał: vas. 14 - 16:30

Poprzedni sygnał: Sprzedaż

Zwrot: -2.04 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	543 365
Średni wolumen	1.14M
Kapitalizacja rynkowa	1.50B
EPS	$0 ( 2024-02-27 )
Następna data zysków	( $-0.560 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.45
ATR14	$0.0160 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-29	Doyle Thomas James	Sell	594	Common Stock
2024-01-29	Doyle Thomas James	Sell	761	Common Stock
2024-01-29	Doyle Thomas James	Sell	963	Common Stock
2024-01-29	Bair Teresa Brophy	Sell	2 053	Common Stock
2024-01-29	Ford Kathleen	Sell	1 496	Common Stock

INSIDER POWER
42.13
Last 95 transactions
Buy: 6 371 376 \| Sell: 2 723 562

Wolumen Korelacja

Długi: 0.46 (neutral)

Krótki: -0.82 (strong negative)

Signal:(62.055) Neutral

Kura Oncology Inc Korelacja

10 Najbardziej pozytywne korelacje
RMRM	0.943
GAINL	0.888
LQDT	0.876
TRVN	0.857
SLNH	0.85
QTEK	0.834
SWVL	0.825
HYMC	0.824
VYNT	0.817
LITM	0.808

10 Najbardziej negatywne korelacje
FANH	-0.844

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kura Oncology Inc Korelacja - Waluta/Towar

0.16
( neutral )

0.24
( neutral )

0.00
( neutral )

0.28
( neutral )

0.13
( neutral )

-0.37
( neutral )

Kura Oncology Inc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-849 000 (0.00 %)
EPS:	$-2.08

FY	2023
Przychody:	$0
Zysk brutto:	$-849 000 (0.00 %)
EPS:	$-2.08

FY	2022
Przychody:	$0
Zysk brutto:	$-759 000 (0.00 %)
EPS:	$-2.03

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.970

Financial Reports:

No articles found.

Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.